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Duchenne muscular dystrophy is a severe inherited muscle disease that affects 1 in 3500 boys worldwide. Infiltration of skeletal
muscle by inflammatory cells is an important facet of disease pathophysiology and is strongly associated with disease severity in
the individual patient. In the chronic inflammation that characterizes Duchenne muscle, cytokines and chemokines are considered
essential activators and recruiters of inflammatory cells. In addition, they provide potential beneficiary effects on muscle fiber
damage control and tissue regeneration. In this review, current knowledge of cytokine and chemokine expression in Duchenne
muscular dystrophy and its relevant animal disease models is listed, and implications for future therapeutic avenues are discussed.
1. Introduction
Duchennemuscular dystrophy (DMD) is an X-linkedmuscle
disease, with a prevalence of 1 in 3500 boys worldwide.
Patients develop progressive weakness of skeletal and respi-
ratory muscles and dilated cardiomyopathy. Clinical onset
is usually between 2 and 5 years of age. Most patients loose
independent ambulation in their teens, after which scoliosis
develops. Death usually occurs before forty years of age and
is most often the result of respiratory or cardiac failure.
The biochemical cause of DMD is a severe deficiency of
dystrophin, an essential component of the sarcolemmal dys-
trophin-associated glycoprotein complex. When complex
assembly is disturbed, the linkage between the muscle cell’s
cytoskeleton and the extracellular matrix is compromised,
leading to sarcolemmal instability and increased vulnerability
to mechanical stress [1]. Fibers undergo necrosis by excessive
Ca2+ influx [2] and are progressively replaced by connective
and adipose tissue.
The immune system plays a pivotal role in the pathogen-
esis of DMD. Contraction of dystrophin deficient myofibers
produces severe damage and generates cycles of muscle
fiber necrosis and regeneration. Necrotizing myofibers are
attacked by macrophages; inflammatory cells are present
throughout the endomysial, perimysial, and perivascular
areas. Macrophages are the most abundant immune cells
observed in DMD muscle and both proinflammatory M1
phenotype macrophages and regeneration-focussed M2 phe-
notype macrophages are present. Within the inflammatory
areas, few T cells, B cells, and dendritic cells are also present.
Infiltrating T cells are predominantly CD4+, and smaller
numbers of CD8+T cells can be found [3].TheT cell receptor
repertoire of CD4+ and CD8+ T cells does not display
dominant V𝛼 or V𝛽 rearrangements, which points toward a
nonspecific cell recruitment to sites of muscle fiber destruc-
tion [4]. In addition to their involvement in muscle damage,
T cells also play an important role in the fibrotic processes
present in dystrophic muscle. T cell deficiency significantly
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reduces collagen matrix accumulation in the murine disease
model [5]. The underlying mechanisms are complex and rely
on the interplay of immune cells and cytokines [6].
The build up of the inflammatory response is complexly
regulated through interactions between adhesion molecules,
receptors, and soluble factors, recruiting immune cells from
the blood stream to the muscle tissue [7].
2. Animal Models of DMD
In the last decade, improved genetic testing has made diag-
nosticmuscle biopsies redundant inmost cases, whichmeans
that nowadays DMD muscle samples only rarely become
available for pathological research. It is therefore even more
imperative to investigate animal models to gain insight into
human disease.This is a feasible approach, as the dystrophin-
associated protein complex is evolutionary ancient and highly
conserved among species. By far the most studied model
for DMD is the murine mdx model. Mdx mice have a
premature stop codon in the dystrophin gene, which leads to
the loss of functional protein. One should however remain
cautious when extrapolating data obtained in the mdx model
to human disease. The clinical phenotype of mdx mice is
less severe and follows a different time course than human
disease. Also, of importance in the context of this review,
there are notable differences in the cytokine system of mouse
compared to man. Dystrophin-deficient dogs seem to more
closelymimic human disease, for example, the severemyopa-
thy in golden retriever muscular dystrophy (GRMD) [8].
Dystrophin-deficient hypertrophic feline muscular dystro-
phy (HFMD) is characterized by early disease onset and
continuous muscle fiber regeneration in the absence of
significant inflammatory infiltration or proliferation of con-
nective or adipose tissue. Some HFMD-affected cats develop
cardiomyopathy [9]. Recently, zebrafish with mutations in
the sapje locus containing the dystrophin gene have become
available. Zebrafish embryos represent a convenient model to
study disease [10] and are extremely suited to first-line drug
screening [11]. It is to be expected that studies inDMDdisease
models, addressing the underlying disease mechanisms as
well as therapeutic efficiencies, will continue to proliferate in
the near future.
3. Cytokines
Initially, no distinct pattern of cytokine expression could be
shown for DMD [12], but since then several inflammatory
factors have been reported to preferentially associate with the
disease [13].
3.1. TNF Family of Cytokines. Theproinflammatorymembers
of the tumor necrosis factor (TNF) family are important
regulators of chronic inflammation. TNF-𝛼 (TNFSF2), the
prototypic catabolic cytokine and most studied member of
the TNF-family, is associated with helper T cell type-1-(Th1-)
mediated cellular immunity. TNF-𝛼 is upregulated in DMD
sera [14] with levels increased 1000 times in comparison
to levels in healthy subjects [15]. TNF-𝛼 mRNA expression
is significantly higher in circulating lymphocytes of DMD
patients compared to controls [16]. In DMD skeletal muscle
tissues, a proportion of muscle fibers are TNF-𝛼 immunore-
active [17] most of which are regenerating muscle fibers [18].
However, the primary source of TNF-𝛼 in DMD muscle is
the inflammatory cells (Figure 1(a)) that, by doing so, further
perpetuate the inflammatory response. Diaphragm of mdx
mice contains significantly higher TNF-𝛼mRNA levels than
controls [19], and TNF-𝛼 protein strongly colocalizes with
tissue infiltrating macrophages [20]. In contrast to what was
expected, TNF-𝛼 knockout mdx mice do not exhibit an
amelioration of muscle pathology [21], adding nuance to
the considered destructive role of TNF-𝛼 in muscle dys-
trophy. Lymphotoxin-𝛽 (LT-𝛽; TNFSF3) is a key factor in
lymphoneogenesis and, through the expression of adhesion
molecules, cytokines and chemokines, it regulates innate and
adaptive immune responses. LT-𝛽 protein levels are signif-
icantly upregulated in muscular dystrophies, compared to
normal skeletal muscle. Blood vessels and the sarcolemma
of DMD fibers are LT-𝛽 positive, and staining is further
enhanced in the regenerating fibers, sometimes accompanied
with sarcoplasmic staining [22]. LT-𝛽 expressed by muscle
fibers could serve as an anchor point to attract inflammatory
cells to the tissue sites.
Muscle fiber necrosis, an accidental form of cell death
triggered by physical tissue damage, is an abundant phe-
nomenon in DMD. However, regulated forms of cell death
could alternatively be involved in muscle damage develop-
ment. Recently, a regulated form of necrosis, which can
be initiated by TNF-𝛼-induced receptor-interacting protein
kinase activity, has been recognized [23]. In addition, the
well-characterized process of apoptosis follows a series of
programmed events, relying upon regulated expression of
specific proteins that signal cells to their death. DNA frag-
mentation and changes in cell structure characteristic to
apoptotic processes can be observed in soleus muscle from
mdx mice [24]. Also, the percentage of apoptotic nuclei is
higher in DMD muscle than in controls [25]. Several TNF
cytokine family members are actively involved in apoptosis.
FasL (TNFSF6) has been shown to inducemuscle cell apopto-
sis in vitro [26]. FasLmRNA expression is significantly higher
in peripheral blood lymphocytes of DMD patients com-
pared to controls [16]. A small proportion of DMD muscle
fibers express the corresponding receptor Fas [27]. Induction
of both ligand and receptor could, unlike in idiopathic
inflammatory myopathies [28], indicate an involvement of
Fas/FasL—mediated apoptosis in DMD muscle atrophy and
degeneration. TNF-like weak inducer of apoptosis (TWEAK;
TNFSF12) is a major inducer of muscle wasting [29] and
preventer of muscle regeneration [30]. To our knowledge, no
data is available at this moment regarding TWEAK expres-
sion in DMD.
3.2. Interleukins. Interleukins (IL), of which 36 different
forms have been identified so far, play a major role in the
immune system. Most important data available at this mo-
ment will be discussed under this heading, except for IL-8
which will be discussed in the chemokine section.
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Figure 1: Immunofluorescent detection of TNF-𝛼 and IFN-𝛾 in Duchenne muscular dystrophy. (a)-(b) Muscle biopsy taken from an 8-year-
old patient with Duchenne muscular dystrophy caused by duplication of dystrophin exon 2, resulting in severe muscle damage, few groups of
revertant fibers, and strong utrophin staining. TNF-𝛼 (red in (a)) is detected in a small cluster of inflammatory cells and colocalizes with CD3
(green in (b)). The asterisk is an indicative that helps to identify an individual TNF-𝛼+ T cell. (c)-(d) Muscle biopsy taken from a 2-year-old
patient with Duchennemuscular dystrophy caused by c.5299-5302dupATTT in dystrophin exon 37.Myopathological evaluation of the biopsy
described definite muscle damage, few groups of revertant fibers, and strong utrophin staining. IFN-𝛾 (red in (c)) is strongly expressed on
the blood vessel endothelium (arrow) and on perivascular CD3+ T cells (green in (d)). Highlighted are an IFN-𝛾+ CD3+ T cell attached to
the luminal side of the blood vessel (asterisk) and an interstitial IFN-𝛾+ CD3+ T cell (circle).
The involvement of proinflammatory IL-1 in muscular
dystrophy remains a topic of debate. Neither IL-1𝛼 nor IL-
1𝛽 immunoreactivity could be shown in a study investigat-
ing 8 DMD muscle samples [17], and the IL-1 family has
been reported downregulated in DMD serum [31]. However,
another study describes IL-1𝛽 as being increased in DMD
muscle [32]. Also, diaphragm of mdx mice contains signifi-
cantly higher IL-1𝛽mRNA levels than control mice [19], and
IL-1𝛽 protein colocalizes with the infiltrating macrophages
[20].
IL-6 is a cytokine with both proinflammatory and anti-
inflammatory properties. It is a helper T cell type 2 (Th2)
cytokine, meaning that it promotes IgE and eosinophilic
responses in atropy and counteracts Th1-driven proinflam-
matory responses. On the other hand, IL-6 exhibits proin-
flammatory activity through activation of the transcription
factor nuclear factor 𝜅B. IL-6 concentrations are significantly
higher in serum of DMD patients (3.77 ± 2.71 pg/mL) com-
pared to healthy age-matched controls (1.93 ± 1.38 pg/mL)
[31] and follow the disease time-course [32]. In DMDmuscle,
IL-6 mRNA levels display a significant increase compared to
controls. The level increases with age: from 26-fold at age 4
years to 148-fold between 5 and 9 years [33]. Blocking IL-
6 through injection with a monoclonal antibody causes an
increase of muscle inflammation in the mdx mouse model,
further suggesting an anti-inflammatory effect, possibly by
mediating muscle repair [34].
IL-10 functions as a suppressor of inflammation through
its differential effect on the different macrophage subtypes:
deactivating M1 macrophages and activating the M2 phe-
notype. M1 macrophages function within the Th1 response
and produce copious amounts of proinflammatory cytokines,
while M2 macrophages promote angiogenesis and tissue
repair and remodeling [35], a phenomenon also present in
muscle [36]. IL-10 prevents the production of Th1-associated
cytokines such as TNF-𝛼 and IFN-𝛾 [37]. Its expression is 8
to 15-fold increased in mdx quadriceps compared with wild
type muscle, possibly as a protective reflex of the tissue. IL-10
null mutation causes severe reduction of muscle strength due
to an imbalance between M1 and M2 macrophages [38].
IL-15 has proinflammatory characteristics as a stimulator
of T cell proliferation and NK-activity but can also be of
benefit to tissue recovery by increasing myogenic differen-
tiation [39]. Mdx diaphragm contains some IL-15 reactivity
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especially in proximity of inflammatory cells. Treatment with
recombinant IL-15 has a mild anabolic effect on diaphragm
function [40].
IL-17 is a potent amplifier of ongoing inflammation and
plays an important role in the progression of chronic inflam-
mation and autoimmunity. IL-17 induces TNF-𝛼, IL-1𝛽, and
IL-6 expression and stimulates the production of chemokines
such as CXCL1, CXCL5, IL-8, CCL2, and CCL7 [41]. In
DMDquadricepsmuscle IL-17mRNA is induced while being
undetectable in control muscle, and expression is associated
with functional outcome at 6 years of age [42].
3.3. Interferons. The interferon (IFN) family members are
divided among three classes. Type I IFN (in humans IFN-𝛼,
IFN-𝛽, and IFN-𝜔) are associated with innate immunity.The
sole human IFN type II is the proinflammatoryTh1 cytokine
IFN-𝛾. IFN-𝛾 expression is elevated in mdx muscle in the
early disease stage when many M1 macrophages are present
[43]. In the regenerating stage of disease, IFN-𝛾 ablation
causes a significant reduction in muscle fiber injury, an effect
probably mediated through the observed shift in favor of M2
phenotype macrophages [44]. In DMDmuscle, the strongest
IFN-𝛾 expression is observed in the blood vessel endothelial
cells and in interstitial T cells (Figure 1(c)).
3.4. Transforming Growth Factors. Transforming growth fac-
tors (TGF) are a large group of cytokines that include TGF-𝛽
1 to 3 andmyostatin. Several members of the TGF family play
important roles as regulators of skeletal muscle homeostasis
and have been implicated in inherited and acquired muscle
disorders.
TGF-𝛽 is a pleiotropic cytokine with important roles in
inflammation, cell growth, and tissue repair [45]. TGF-𝛽 is a
fibrogenic cytokine that induces synthesis and accumulation
of extracellular matrix components. In adult muscle, TGF-
𝛽 negatively affects skeletal muscle regeneration by inhibit-
ing satellite cell proliferation and myofiber fusion. TGF-𝛽1
mRNA levels are significantly higher in 30-day-old GRMD
than in healthy dogs. TGF-𝛽 immunoreactivity ismostly con-
fined to the connective tissue and varies between individual
animals. Interestingly, in adult GRMD dogs TGF-𝛽 mRNA
levels decrease to levels lower than those in normal dogs
[46]. TGF-𝛽1 activation appears to be associated with muscle
wasting in DMD. TGF-𝛽1 expression, mostly originating
from muscle resident fibroblasts, is most pronounced in the
early stages of muscle fibrosis and peaks between 2 and 6
years of age [47]. Fibroblasts from DMD muscle biopsies
differ from control fibroblasts, displaying higher rates of
proliferation. In addition, DMD muscle-derived fibroblasts
contain significantly higher TGF-𝛽 protein levels, though
similar levels of TGF-𝛽1 mRNA are present as in controls
[48]. Of special interest to determine patient prognosis is that
a haplotype of the latent TGF-𝛽 binding protein 4 gene has
been shown to correlate with prolonged ambulation of DMD
patients [49].
Skeletal muscle specific myostatin (TGF-𝛽8) is an
inhibitor of muscle growth. Mdx mice lacking myostatin dis-
play less fibrosis in the diaphragm and are stronger and more
muscular than their normal mdx counterparts [50]. Another
study found that myostatin is downregulated in muscle from
DMD infants as well as symptomatic patients [51] indicating
that this pathway may contribute less to muscle wasting in
humandisease.Myofibroblasts prepared fromDMDbiopsies,
however, have been shown to express significantly higher
myostatin mRNA levels than controls [48].
4. Chemokines
Chemotactic cytokines or chemokines are subdivided into
families according to their primary structure (most belong
to the alpha (CXCL) or beta (CCL) families) and exert
their biological functions by binding to G protein-coupled
receptors [52]. Chemokines interact with other cytokines
and adhesion molecules and their activities go way further
than the attraction of leukocytes to inflammatory sites.
CCL17, for instance, has been shown to enhance tissue
fibrosis [53]. While the chemokine expression profile in
healthy skeletal muscle is fairly limited, many chemokines are
induced or upregulated in dystrophic muscle (Tables 1 and
2) [54–58]. The individual muscle tissue distribution of some
chemokines has been determined and shows that they can
differentially be allocated to inflammatory cells, blood vessel
endothelium, and/or the muscle fibers themselves (Figure 2).
Three chemokines, being CXCL8 (IL-8), CCL2, and CCL5,
come forward as possible effectors of the cytotoxic activities
ofM1macrophages inDMD.CCL2upregulation in particular
seems an early event in muscle dystrophy, present in DMD
before the age of 2 years [55] and detectable in 14-day oldmdx
mice [57].
5. Comparison with Myositis of Other Origins
Muscular dystrophies are a clinically, biochemically, and
genetically heterogeneous group of disorders [59]. Dystro-
phin mutations are not just responsible for DMD but also
cause a spectrum of other X-linked conditions, such as
the milder Becker muscular dystrophy (BMD), cardiom-
yopathies, and mental retardation. Also, defects in other
dystrophin-associated proteins cause disease, including auto-
somal recessive inherited limb-girdle muscular dystrophies.
In many subtypes, muscle inflammation and muscle wast-
ing contribute to disease progression, potentially implicat-
ing cytokines and chemokines in their pathogenesis. For
instance, the presence of endomysial and perivascular inflam-
mation is an established hallmark of dysferlinopathy [60].
In contrast to the relatively limited amount of published
DMD data, a multitude of reports is available on the expres-
sion of cytokines in the different idiopathic inflammatory
myopathies (IIM), which include dermatomyositis (DM),
polymyositis (PM) and sporadic inclusion body myositis
(IBM) [61]. This allows for some comparison between pri-
mary muscle inflammation in IIM and dystrophy-associated
muscle inflammation. In a single BMD patient included in
a multiplex cytokine immunoassay study, CCL2 levels are
11 pg/mg muscle protein, while those in 6 patients per IIM
group were 45 ± 51 (DM), 15 ± 9 (PM) and 13 ± 9 (IBM),
Mediators of Inflammation 5
Table 1: Alpha-chemokine expression in Duchenne muscular dystrophy and its mouse model.
Systematic name Common name Tissue mRNA quantity Protein quantity Protein localization Reference
CXCL1 GRO-alpha DMD quadriceps muscles BV, MF, M𝜑, T, DC [54]
CXCL2 GRO-beta DMD quadriceps muscles BV, MF, M𝜑 [54]
CXCL3 GRO-gamma DMD quadriceps muscles BV, MF, M𝜑, DC [54]
CXCL8 IL-8 DMD quadriceps muscles BV, MF, M𝜑 [54]
CXCL10 IP-10 DMD quadriceps muscles BV, (MF), M𝜑, T [54]
CXCL11 ITAC DMD quadriceps muscles BV, (MF), M𝜑 [54]
CXCL12 SDF-1 DMD quadriceps muscles Increased 2.3x [55]
DMD quadriceps muscles BV, MF [54]
DMD serum Increased 1.2x [56]
CXCL14 BRAK mdx hindlimb muscles Increased 1.7x [57]
Breast and kidney derived (BRAK); blood vessel (BV), alpha-chemokine (CXCL), dendritic cell (DC), Duchennemousemodel (mdx), growth related oncogene
(GRO), interleukin 8 (IL-8), interferon-inducible protein of 10 kd (IP-10), interferon-inducible T cell alpha chemo-attractant (ITAC), muscle fiber (MF),
macrophage (M𝜑), stromal cell-derived factor (SDF), T cell (T). Rare observations are indicated between brackets.
Table 2: Beta-chemokine expression in Duchenne muscular dystrophy and its mouse model.
Systematic name Common name Tissue mRNA quantity Protein quantity Protein localization Reference
CCL2 MCP-1 mdx hindlimb muscles Increased 62.7x Increased 4.1x MF, M𝜑 [57]
DMD quadriceps muscles Increased 1.4x [55]
BV, M𝜑 [54]
CCL3 MIP-1 alpha mdx diaphragm Increased [58]
CCL5 RANTES mdx hindlimb muscles Increased 2.3x [57]
mdx diaphragm Increased Increased [58]
DMD quadriceps muscles M𝜑 [54]
CCL7 MCP-3 mdx hindlimb muscles Increased 14.7x [57]
DMD quadriceps muscles M𝜑 [54]
CCL8 MCP-2 mdx hindlimb muscles Increased 28.9x [57]
CCL9 MIP-1 gamma mdx hindlimb muscles Increased 7.9x Increased 2.4x [57]
CCL11 eotaxin mdx hindlimb muscles Increased 2.0x [57]
CCL17 TARC DMD quadriceps muscles (M𝜑) [54]
Blood vessel (BV), beta-chemokine (CCL), Duchennemuscular dystrophy (DMD),monocyte chemoattractant protein (MCP), Duchennemousemodel (mdx),
muscle fiber (MF), macrophage (M𝜑), macrophage inflammatory protein (MIP), regulated upon activation, normal T cell expressed and secreted (RANTES),
thymus and activation-regulated chemokine (TARC). Rare observations are indicated between brackets.
respectively [62]. In DMD quadriceps muscle, TNF-𝛼, IL-
6, and CCL2 mRNA levels are lower than in juvenile DM
[42]. The observed more moderate expression levels could
be indicative to the secondary nature of muscle inflam-
mation as opposed to the primary inflammatory origin of
the IIM. Although there unmistakably are universal inflam-
matory processes at hand, data also point to specific roles
for cytokines and chemokines in DMD. The expression pro-
files of M1 macrophages are peculiar when DMD and IIM
are compared. Also, in IIM strong expression of CXCR3 is
observed on the muscle infiltrating T cells, indicating their
involvement inTh1 immune responses. Such polarization of T
cells is less obvious in DMDmuscle. In fact, the muscle infil-
trating T cells in DMD express a strikingly limited repertoire
of chemokines in comparison to their IIM counterparts [54].
6. Relevance to DMD Disease Management
The medical community still awaits the coming of age of
molecular dystrophin salvaging therapies [63]. In this respect,
exon skipping [64] and suppression of stop codons [65]
are considered strategies of increasing functional dystrophin
expression. However, surfacing results of clinical trials, more
particular those using AAV-mediated delivery of mini-
dystrophin, are suggestive of important acquisition of T cell
immunity targeting the dystrophin protein [66]. Earlier, it
had been postulated that such priming was unlikely, due to
the presence of revertant fibers inmany patients which would
theoretically safeguard dystrophin replacement from the
immune system. Nonetheless, it is becoming more and more
obvious that monitoring of cellular immune responses will
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Figure 2: Chemokine staining in Duchenne muscular dystrophy. Nonconsecutive sections showing the same microscopic field containing a
necrotic muscle fiber invaded by macrophages (asterisk). The muscle biopsy was taken from an 8-year-old patient with Duchenne muscular
dystrophy caused by duplication of dystrophin exon 2. Upon diagnostic myopathological evaluation, the biopsy displayed severe muscle
damage, few groups of revertant fibers, and strong utrophin staining. Chemokines were immunostained and visualized with a secondary
antibody using the streptavidin-biotin labeling system and 3-amino-9-ethylcarbazole chromogen (Dako, Glostrup, Denmark). Cell nuclei
were counterstained with hematoxylin (blue). The sarcoplasm of a necrotic fiber is strongly positive for CXCL8 (red in (a)) and CXCL11 (red
in (b)). The cytoplasm of the necrotic fiber and its invading inflammatory cells are moderately positive for CCL5 (red in (c)) and faintly
positive for CCL17 (red in (d)). Small regenerating fibers stain for all four chemokines with varying intensities.
be a priority in all ongoing and future experimental therapies
aimed at increasing the number of dystrophin positivemuscle
fibers. A recent study demonstrated that circulating dys-
trophin primed T cells are frequently encountered in DMD,
increased with age, and reduced by glucocorticoid therapy
[67].
Immunosuppression, administering glucocorticoids in
particular, remains standard treatment for DMD today.
Although anti-inflammatory therapy may add years to DMD
patient ambulation, steroids are associated with important
adverse effects [68]. The characterization of the factors that
drive inflammation and guide specific subsets of leuko-
cytes to the tissues raises hopes of attempting more selec-
tive immunomodulatory intervention. Strategies aimed at
neutralizing individual cytokines or chemokines could be an
amenable approach to reduce side effects.
6.1. Targeting the Culprits While Sparing the Protectors. Spe-
cifically targeting cytokines and chemokines with predom-
inant proinflammatory activities, such as TNF-𝛼, is under
exploration. The TNF-𝛼 neutralizing antibody infliximab
delays and reduces muscle damage in mdxmice [69]. Soluble
TNF-receptor etanercept, a dimeric fusion protein composed
of an extracellular ligand-binding portion of the human p75
TNF-receptor linked to the Fc portion of human IgG, reduces
muscle fibrosis [70] and necrosis [71]. The disruption of
chemokine-mediated signaling also seems, at first glance, an
attractive therapeutic possibility. An approach could be to
selectively block a chemokine receptor with a key catabolic
role by either a small-molecule antagonist, antibody, binding
protein, or protein agonist [72]. Several chemokine-receptor
antibodies are entering the clinic, including an anti-CCR2
monoclonal antibody namedMLN1202 (Millenium Pharma-
ceuticals, Cambridge, MA, USA) currently being tried for
various inflammatory diseases. However, strategies targeting
the chemokine system present with certain inherent difficul-
ties. Firstly, several chemokines are up-regulated in DMD.
The redundancy of function of part of themmakes it difficult
to design effective therapeutic interventions. Secondly, there
could be considerable inter-patient variability, as well as
differences between the stages of the disease. More research
is necessary to address these issues. Thirdly, chemokines can
have benefits for tissue recovery, by activating muscle fiber
regeneration and recruiting non-cytotoxic macrophage sub-
populations that stimulate muscle tissue rebuilding [73]. For
instance, when considering the anti-CCR2 avenue, its ligand
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CCL2 has the potential to drive forward chronic inflamma-
tion, but the importance of CCL2 in muscle regeneration has
also been recognized [74, 75].
In addition, strategies aimed at neutralizing fibrogenic
cytokines or cytokines associated with muscle wasting are
under exploration for treating DMD. For instance, the TGF-
𝛽1 antagonist pirfenidone improves cardiac function in mdx
mice [76]. The TGF-𝛽 blocker suramin decreases fibrosis
and offers benefit in grip strength in mdx mice [77]. A
TGF-𝛽 neutralizing antibody decreases fibrosis and improves
regeneration in mdx mice [78]. Inhibition of myostatin with
a neutralizing antibody [79], soluble decoy receptor [80], or
myostatin binding propeptide [81] has also been put forward.
An in vitro model, using nodules of DMD muscle-derived
fibroblasts grown onto a solid substrate, has been developed
which allows convenient screening of potential antifibrotic
agents [82].
6.2. Reprogramming the Immune Response. WhileM1macro-
phages have a destructive cytokine repertoire, the M2 phe-
notype promotes angiogenesis, tissue repair, and remodeling.
In mdx muscle, M1 macrophages predominate during the
early, acute stage. The balance tips over to the M2 phenotype
in the regenerative and progressive phase of the disease. In
other words, the M1/M2 balance evolves beneficially with
M1 macrophages undergoing deactivation as the disease pro-
gresses from the acute necrotic to the regenerative phase. M1
density significantly reduces with age in mdx soleus (4 versus
12 weeks) [43]. This could account for the milder disease
phenotype of mdx mice compared to human disease, as in
contrast percentages of M1 and M2 phenotype macrophages
seem strikingly constant in DMD muscle taken at different
disease stages [54]. Therapeutic agents regulating the M1/M2
balance in favor of the M2 phenotype, such as cannabinoid
CB2 receptor agonists, could be of benefit to patients [83].
Interestingly, glucocorticoids as such have also been shown
to favor a shift of macrophage phenotype, reducing the
numbers of M1 macrophages by half in patients treated with
prednisone (0.75mg/kg/day) during 6 months [84].
7. Conclusions
In dystrophic skeletal muscle, part of the accumulating mus-
cle damage is caused by ongoing activation of inflammatory
cells rather than by direct mechanical damage. Current
knowledge, of which a large part is summarized in this review,
supports an important and diversified role for cytokines and
chemokines in the DMD-associated muscle inflammation.
The fact that a number of chemokines are expressed directly
by the muscle fibers suggests that the tissue itself contributes
to the chemotaxic process, actively perpetuating the chronic
inflammation.
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